Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...

PFE currently has a forward P/E ratio of 7.57, while LLY has a forward P/E of 32.57. We also note that PFE has a PEG ratio of 0.84. This metric is used similarly to the famous P/E ratio, but the ...

During the 2022 inflation shock, LLY stock saw a 19% decline, and it fell 23% during the 2020 COVID-19 pandemic market correction. However, when compared to the broader market, ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that ...

Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our P/B Growth Investor model based on the published strategy of ...

A caller asked what Cramer’s thoughts on Eli Lilly and Company (NYSE:LLY) were, and he commented: “Okay, Eli Lilly. We bought some just the other day for the Charitable Trust.

With a trading volume of 1,509,635, the price of LLY is up by 1.2%, reaching $722.3. Current RSI values indicate that the stock is may be approaching oversold.